Strategic Partners

Tranzyme's business strategy is to use its unique, proprietary chemistry to discover breakthrough therapeutics for high-value, intractable drug targets, and to develop drugs which address diseases with significant unmet medical need. Tranzyme's strategy is to license certain rights to these drugs when proof of concept in man is achieved, or when a program may benefit from the research, development and commercialization capabilities of a partner. Through these strategic partnerships, Tranzyme intends to balance risk while preserving the potential for significant returns.

Tranzyme entered into a strategic collaboration agreement with Bristol-Myers Squibb (NYSE: BMY) in December 2009 to discover, develop and commercialize novel macrocyclic compounds derived from Tranzyme's proprietary drug discovery technology, in diverse therapeutic areas.

Tranzyme is pursuing partnership discussions for the following programs:

TZP-101 for Gastrointestinal (GI) Motility Disorders in Acute Care Settings

TZP-101, Tranzyme's intravenous ghrelin agonist, is being evaluated clinically for use as a prokinetic agent in acute care settings for the management of GI motility disorders. The drug is poised for Phase 3 studies in two indications: postoperative ileus (POI) and gastroparesis.

TZP-102 for Gastroparesis and Other GI Motility Disorders

TZP-102 is an orally-administered compound that shares the potent prokinetic attributes of TZP-101 while being a chemically distinct molecule, and is in development for the treatment of gastroparesis and selected potential additional indications such as GERD, functional dyspepsia, and cancer cachexia. TZP-102 is particularly well-suited for long-term oral therapy required by the chronic nature of gastroparesis and other unremitting GI motility disorders.

TZP-201 for Moderate-to-Severe Diarrhea

TZP-201 is a motilin antagonist currently in the preclinical efficacy profiling and drug development stage. The initial targeted indications for TZP-201 are chemotherapy-induced diarrhea, diarrhea associated with infection, and diarrhea associated with irritable bowel syndrome. Tranzyme is interested in initiating partnering discussions with companies that wish to expand their product portfolios in the oncology supportive care and anti-infective disease areas.

Chemistry-Based Drug Discovery

Tranzyme Pharma has developed its product portfolio using its breakthrough, proprietary macrocyclic small molecule chemistry technology, MATCH™. These macrocyclic small molecules have many distinct advantages over other drug discovery approaches: agonists as well as antagonists can be developed, synthesis is simple, cost of goods is low, and good PK, ADME, and oral bioavailability properties can be easily developed. Drug target classes of particular interest are GPCRs, proteases, kinases, ion channels and protein-protein interaction targets.

Tranzyme is seeking to complement its product portfolio with chemistry-based drug discovery partnerships. Our chemistry program business strategy is to enter into high-value partnerships with leading pharmaceutical and biotechnology companies in which Tranzyme contributes this chemistry technology, and its extensive discovery chemistry and medicinal chemistry expertise, and the partner contributes the drug targets, drug target biology and expertise in the target area. These collaborations will allow the partner to develop many promising drug leads, and provide a significant competitive advantage in its field using this breakthrough chemistry technology.

To discuss these opportunities, please contact Tranzyme's Business Development Department:

Jennifer A. Filbey, Ph.D.
Vice President, Business Development

Phone: (256) 417-8568